Methods of treatment using IL-31RA
The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.
1. A method of treating a patient with prurigo nodularis, comprising administering a therapeutically effective amount of a soluble IL-31RA homodimeric receptor to the patient, wherein the soluble IL-31RA homodimeric receptor comprises amino acid residues 20-519 of SEQ ID NO:6 fused to the Fc region of an immunoglobulin.
2. The method of claim 1 , wherein the immunoglobulin Fc region is of IgG, IgA, IgD, IgM or IgE.
3. The method of claim 1 , wherein the soluble IL-31RA homodimeric receptor binds with an IL-31 polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2.